• Explore /
  • Poster
  • / A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors.

A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors.

Abstract Poster

Authors

null

Ursula A. Matulonis

Dana-Farber Cancer Institute, Boston, MA

Ursula A. Matulonis , Filip Janku , Justin C Moser , Siqing Fu , David S. Wages , Catherine A. Wheeler , Mikinaga Mori , Susumu Shimoyama , Naoki Yamada , Ruth Ann Subach , Kin Cheung , Timothy Madden , Gary Maier , Mary Johansen , Gerald Steven Falchook

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT04047251

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3101)

DOI

10.1200/JCO.2022.40.16_suppl.3101

Abstract #

3101

Poster Bd #

93

Abstract Disclosures

Similar Posters

First Author: Judy S. Wang

First Author: Apostolia Maria Tsimberidou

First Author: Miguel Angel Villalona-Calero

First Author: Patricia LoRusso